erdafitinib-releasing intravesical system tar-210
Generic: Erdafitinib-releasing Intravesical System TAR-210
erdafitinib-releasing intravesical system tar-210: 1 clinical trial tracked.
erdafitinib-releasing intravesical system tar-210 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about erdafitinib-releasing intravesical system tar-210, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
Clinical Trial Registry Records (1)
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)
Primary endpoint: Disease-free Survival (DFS)
InterventionalRandomizedopen220 targetStarted 2025-09Completion 2032-0350 sites · Argentina, Belgium, Brazil, China…Janssen Research & Development, LLC